GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: EBL-3599 is from a series of antibacterial compounds that target UDP-2,3-diacylglucosamine hydrolase (LpxH), an essential enzyme in the lipopolysaccharide synthesis pathway, that is conserved in the majority of Gram-negative bacteria but absent in human [1]. EBL-3599 is a derivative of JEDI-1444 and was identified as part of a programme to develop LpxH inhibitors with activity against efflux-proficient Gram-negative bacteria.
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| EBL-3599 exhibits Gram-negative antibacterial activity and is effective against efflux-proficient strains of Escherichia coli and Klebsiella pneumoniae [1]. It has improved drug-like properties, compared to earlier inhibitors from the series, and shown to have in vivo efficacy against E. coli and K. pneumoniae in a mouse peritonitis model [1]. EBL-3599 inhibits E.coli LpxH with an IC50 of 3.5 nM [1]. |